Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00159770
Status:
COMPLETED
Last Update Posted:
2021-02-21
First Post:
2005-09-08
Brief Title:
Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
Tolerability Safety And Efficacy Of Ziprasidone 80 - 160 MgD Versus Olanzapine 10 - 20 MgD Risperidone 4 - 8 MgD Or Quetiapine 300 - 750 MgD In Pretreated Patients With Schizophrenia Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label Multicenter Clinical Trial
Status:
COMPLETED
Status Verified Date:
2021-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine risperidone or quetiapine in patients with schizophrenia schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None